Amivantamab
Based on 3 publication(s) in Google Scholar
Amivantamab (JNJ-61186372) is a human EGFR-MET bispecific antibody with immune anticancer activity. Amivantamab inhibits ligand binding, promotes endocytosis and degradation of receptor-antibody complexes, and induces Fc-dependent cytokinesis in macrophages and antibody-dependent cytotoxicity in natural killer cells.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 99.90%
- CAS No.: 2171511-58-1
- 분자량:145.88 kDa
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Biological Activity
-
Chemical Information
- 순도&문서
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Amivantamab
More
Customer Validation & Images
-
Cell Proliferation/Viability Assay
All EGFR Isoforms
More
Biological Activity
Human IgG1 kappa
Human
EGFR & c-Met
Amivantamab (JNJ-61186372)(0.05-1 mg/mL) results in a significant and dose-dependent decrease in the viability of Ba/F3 cells, as well as a significant decrease in phosphorylated EGFR (pEGFR), phosphorylated AKT (pAKT), phosphorylated ERK (pERK) and phosphorylated S6 (pS6) of the EGFR downstream signaling pathway[2].
Amivantamab (JNJ-61186372) has potent antitumor activity in NSCLC patient-derived cancer cells with EGFR Exon20ins mutations through downregulation of EGFR and MET signaling pathways[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
-
Immobilized Human c-MET/HGFR Protein (ECD, His Tag) can bind Amivantamab. The EC50 for this effect is 1.20 ng/mL. -
Immobilized Human EGFR Protein can bind Amivantamab. The EC50 for this effect is 2.58 ng/mL.
Chemical Information
-
CAS No. 2171511-58-1
-
Appearance Liquid
-
분자량 145.88 kDa
-
Color Colorless to light yellow
-
SMILES
[Amivantamab]
-
Synonyms
JNJ-61186372
-
선적
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
Cancer Res
2025 Oct 9. PMID: 41066595 -
J Exp Clin Cancer Res
2023 Nov 4;42(1):292. PMID: 37924112
Amivantamab purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2023 Nov 4;42(1):292. [Abstract]
(A) MDA-MB-231 and (B) BT549 cells were treated with various concentrations of Amivantamab (1–1000 μg/ml) or control vehicle (DMSO) for 72 h.
-
Clin Cancer Res
STX-721, a Covalent EGFR/HER2 Exon 20 Inhibitor, Utilizes Exon 20-Mutant Dynamic Protein States and Achieves Unique Mutant Selectivity Across Human Cancer Models. [Abstract]2025 Jun 4:OF1-OF17. PMID: 40465424
순도&문서
-
Data Sheet (261 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Keunchil Park, et al. Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study. J Clin Oncol. 2021 Oct 20;39(30):3391-3402. [Content Brief]
[2]. Jiyeon Yun, et al. Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC. Cancer Discov. 2020 Aug;10(8):1194-1209. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz